Cisco
CSCO
Alibaba
BABA
Disney
DIS
Apple
AAPL
Qualcomm
QCOM
US Stock MarketDetailed Quotes
CRVS Corvus Pharmaceuticals
- 3.350
- -0.580-14.76%
Close Mar 26 16:00 ET
- 3.450
- +0.100+2.99%
Post 20:01 ET
228.25MMarket Cap-3.28P/E (TTM)
4.285High3.200Low1.95MVolume4.000Open3.930Pre Close6.83MTurnover3.98%Turnover RatioLossP/E (Static)68.14MShares10.00052wk High7.01P/B164.28MFloat Cap1.30052wk Low--Dividend TTM49.04MShs Float22.137Historical High--Div YieldTTM27.61%Amplitude0.607Historical Low3.502Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Corvus Pharmaceuticals Stock Forum
New Cancer Drug Achieves 39% Response Rate in T Cell Lymphoma Patients
Corvus Pharmaceuticals Inc - Data Show Favorable Safety and Efficacy Profile
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Monday, 13th January at 7:30 am
BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with m...
day 2, though im making 1k+ from this NUKE everyday… im just covering loss from pharma… never gonna touch meds again else wld be up 6k+ hahahaha
why everyone are leaving? i thought this is a promising clinical sign???
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile
Data includes complete results from cohort 1 and initial results from cohort 2
Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million
Company to host conference call and webca...
📊⚡️📊
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
$KULR Technology (KULR.US)$ PR 12/17: Signs Service Agreement to Launch KULR ONE Space Battery. COH $13.4M good for 9 months✅
$Wearable Devices (WLDS.US)$ PR 12/17:...
No comment yet